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Many neurodegenerative diseases exhibit protein accumulation and increased oxidative stress. Therapeutic
strategies include clearing aggregate-prone proteins by enhancing autophagy or decreasing oxidative stress
with antioxidants. Many autophagy-inducing stimuli increase reactive oxygen species (ROS), raising con-
cerns that the benefits of autophagy up-regulation may be counterbalanced by ROS toxicity. Here we
show that not all autophagy inducers significantly increase ROS. However, many antioxidants inhibit both
basal and induced autophagy. By blocking autophagy, antioxidant drugs can increase the levels of aggre-
gate-prone proteins associated with neurodegenerative disease. In fly and zebrafish models of
Huntington’s disease, antioxidants exacerbate the disease phenotype and abrogate the rescue seen with
autophagy-inducing agents. Thus, the potential benefits in neurodegenerative diseases of some classes of
antioxidants may be compromised by their autophagy-blocking properties.
INTRODUCTION
Neurodegenerative diseases, such as Parkinson’s disease (PD),
and polyglutamine expansion diseases, such as Huntington’s
disease (HD), represent a significant burden in terms of indi-
vidual morbidity, mortality and wider social and economic
costs (1). Treatment remains only symptomatic as unfortu-
nately there are currently no therapies that modify the pro-
gression of the disease (2). Considerable research activity
has been directed towards understanding common pathologi-
cal mechanisms that might be amenable to therapeutic inter-
vention. Oxidative stress is one common feature of these
diseases that has been extensively investigated (3). Reactive
oxygen species (ROS) are formed by the incomplete reduction
of oxygen and are produced at low levels under normal
physiological conditions as a result of mitochondrial respir-
ation and a number of other processes. The cell is able to
absorb some increase in ROS via a variety of antioxidant
defences. When these defences are overwhelmed, ‘oxidative
stress’ is said to occur and this ultimately leads to cell
death. There is a large amount of in vitro and in vivo evidence
suggesting that oxidative stress occurs during neurodegenera-
tion, and, as a result, ameliorating oxidative stress with antiox-
idant drugs has been a major focus of therapeutic research (4).
A second hallmark of these diseases is the accumulation and
aggregation of misfolded pathogenic proteins. Clearance of
disease-associated proteins, such as mutant alpha-synuclein,
ataxin-3, tau and huntingtin, can be achieved by up-regulating
the bulk protein degradative process of macroautophagy (5).
Furthermore, autophagy seems integral to neuronal health as
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inhibition of autophagy results in neurodegeneration even in the
absence of disease (6). During autophagy, mutant protein is
sequestered along with cytoplasm in a double membrane to
form an autophagosome. Subsequent to fusion of the autophago-
some and lysosome, autophagosomal substrates are degraded.
Autophagy is tightly regulated by a number of pathways, of
which the most extensively studied involves the protein kinase
mTOR (mammalian target of rapamycin), which negatively
regulates autophagy. Inhibition of this pathway with the drug
rapamycin enhances autophagy (7). More recently, drugs that
do not act via mTOR (‘mTOR-independent’ agents) have been
identified (8), and new fundamental mechanisms regulating
autophagy have been described (9). Drugs which up-regulate
autophagy have been shown to alleviate toxicity in mouse
models of HD and spinocerebellar ataxia type 3, and, as a
result, autophagy-enhancing drugs represent an alternative
potential disease-modifying therapy (10,11).
Recently, the themes of oxidative stress and autophagy
have been brought together. Starvation, a classic autophagy-
inducing stimulus, has been shown to increase both cellular
levels of ROS and autophagy (12). One mechanism by which
autophagy appears to be regulated by ROS is the redox regulation
of the essential autophagy protein Atg4 (12). This protein is
required for the conjugation of Atg8 to phosphatidylethanola-
mine, a reaction that is in turn essential for the induction of autop-
hagy. It seems unlikely that this is the only ROS-dependent
mechanism involved, as Atg4 not only lipidates Atg8 when oxi-
dized but is also responsible for delipidating and recycling Atg8
when reduced. Thus, in strong oxidizing conditions, increased
lipidation of Atg8 will initially occur and induce autophagy,
but autophagy may ultimately be inhibited if Atg8 is not recycled.
The importance of autophagy and oxidative stress to both
pathology and potential therapies for neurodegeneration has
led us to investigate their relationship further. A diverse
range of stimuli that induce both ROS and autophagy have
been described and autophagy induction by these agents is
antagonized by antioxidants (13–15). If all autophagy-
inducing drugs increase ROS then this may be a potential
barrier to their use in human sufferers of neurodegenerative
diseases, because the consequent increases in the already
high levels of oxidative stress may outweigh any benefit
from autophagy up-regulation. For this reason, we tested
whether all autophagy-inducing agents also increase oxidative
stress, and found this not to be the case. However, our data
suggest that many ROS scavengers block both basal autop-
hagy and autophagy induced by ROS-independent mechan-
isms. Furthermore, these ROS scavengers can enhance the
toxicity of polyglutamine expansions in flies and zebrafish,
suggesting that the use of such drugs may be limited in the
context of neurodegenerative diseases caused by aggregate-
prone proteins which are also autophagy substrates.
RESULTS
Not all autophagy-inducing drugs are associated with an
increase in ROS
ROS levels are commonly measured using redox sensitive
fluorescent probes and fluorescence-activated cell sorting
(FACS). This technique may be limited, however, as suspension
of cells in phosphate buffered saline (PBS) prior to analysis by
FACS will result in starvation and rapid and large increases in
ROS (12). In order to avoid this potential artefact, we loaded
HeLa cells with one of the three different ROS-sensitive fluoro-
genic probes [dichlorofluorescin diacetate (DCFDA), dihydror-
hodamine 123 and the mitochondrially localized superoxide
detector MitoSOX redTM] before treating them with autophagy
inducers or controls and measured changes in fluorescence over
24 h. Neither rapamycin (an autophagy inducer acting by inhibit-
ing the mTOR pathway), nor trehalose (an autophagy inducer
acting via non-mTOR pathways) increased ROS (Fig. 1A–C).
In fact, trehalose (a disaccharide with putative antioxidant prop-
erties) (16) significantly decreased mitochondrial superoxide pro-
duction (Fig. 1C). In order to be sure there was no late increase in
ROS following treatment with autophagy-inducing agents, we
treated cells for 24 h with rapamycin or trehalose, before
loading with a ROS sensitive probe and measuring change in
signal over 1 h. Again, no increase in ROS following treatment
with rapamycin or trehalose was seen (Fig. 1D). We also investi-
gated the effects of autophagy induction on levels of ROS in a
second cell line (COS-7) in which we have previously character-
ized autophagic activity (17). This cell line is of renal origin and
therefore may be more sensitive to changes in ROS than HeLa
cells. In order to increase the sensitivity of our assay, we used a
derivative of DCFDA which increased cellular retention of the
probe. Though we saw a much greater increase with positive con-
trols, once again we saw no increase in ROS either with rapamy-
cin or trehalose (Fig. 1E). While we cannot absolutely rule out
small increases in ROS induced by rapamycin or trehalose, our
data suggest that these agents do not induce the significant
increase seen with some other autophagy-inducing stimuli, such
as starvation.
Up-regulation of autophagy by rapamycin and trehalose is
impaired by thiol antioxidants
When autophagy induction is mediated by an increase in ROS,
increases in autophagy can be inhibited with ROS scavengers
(12,14). We next tested whether the impairment of autophagy
by antioxidants was limited to situations where the
autophagy-inducing agent also significantly increased ROS. We
tested the ability of a variety of thiol antioxidants (including
those proposed for treatment of HD) (18) to ameliorate the induc-
tion of autophagy by trehalose (which does not increase levels of
ROS) in COS-7 cells. We found that N-acetyl cysteine (NAC),
cystamine [a drug proposed for use in HD, with pleiotropic
effects including transglutaminase inhibition, but which is also
metabolized to the antioxidant L-cysteine (19)] and glutathione
were all able to significantly ameliorate the induction of autop-
hagy by trehalose in a dose-dependent fashion, as measured by
levels of the autophagy marker, microtubule-associated protein
1 light chain 3 II (LC3-II) (Fig. 2A–C). LC3-II is formed from
LC3-I after it is conjugated to phosphatidylethanolamine, an
essential step in autophagy induction. Decreases in levels of
LC3-II can be caused by a decrease in autophagosome formation
or by increase in autophagosome lysosome fusion. As we are
interested in autophagic flux, these experiments were performed
in the presence of a saturating dose of bafilomycin A1, a macro-
lide antibiotic that blocks autophagosome/lysosome fusion (20).
Thus, decreases in levels of LC3-II under these conditions
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Figure 1. Not all autophagy-inducing agents cause an increase in ROS. Neither trehalose or rapamycin cause an increase in levels of ROS. HeLa cells were
loaded with DCFDA (A), dihydrorhodamine 123 (B) or MitoSOXTM red (C), before being treated with H2O2, menadione, rapamycin, trehalose, DMSO or
starved in Hanks Balanced Salt Solution (HBSS). Fluorescent signal was serially measured as described in Materials and Methods. The histograms show
signal at 24 h as percentage of positive control while adjacent line graphs show change from baseline against time over 24 h. (D) Cells were treated with tre-
halose, dimethyl sulfoxide (DMSO), rapamycin or neither for 24 h before being loaded with DCFDA and signal read 1 h later. Treatment with hydrogen peroxide
or starvation for 1 h after loading provided positive controls. Rapamycin and trehalose cause no increase in signal. (E) COS-7 cells were loaded with
Carboxy-H2DCFDA before being treated in a similar way to (A). Only H2O2 and starvation caused significant increases in signal. All experiments were per-
formed with no probe as a negative control (no DCFDA, NoDCFDA; no dihydrorhodamine, NoDHR; no Mito, No MitoSOXTM red; No Carboxy-H2DCFDA,
NoH2DCF). Error bars are present for all data points (but are too small to be seen on some) and show standard error of the mean (SEM) for three independent
experiments in triplicate (NS, not significant, ∗P, 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001).
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Figure 2. Antioxidant drugs inhibit basal and induced autophagy. NAC, cystamine and glutathione all inhibit trehalose-induced autophagy. COS-7 cells were
treated with trehalose and co-treated with the indicated concentrations of NAC (A), pre-treated for 24 h with cystamine (Cys) (B) or co-treated with glutathione
(Glu) (C). After 24 h, a saturating dose of bafilomycin A1 was added for the last 4 h prior to harvest. The graphs below each blot show densitometric analysis of
LC3-II/actin from three experiments performed in triplicate, with the control condition (trehalose alone) set to 100%. (D) NAC impairs rapamycin induced and
basal autophagy. COS-7 cells were treated with 25 mM NAC, rapamycin, rapamycin and NAC, trehalose (Tre) or trehalose and NAC for 24 h. All conditions
were treated with bafilomycin for 4 h prior to harvesting. The graph shows densitometric analysis with no treatment (control) set to 100%. (E) The effects of
NAC on autophagy are also seen in neurons. Differentiated human primary cortical neurons were treated as indicated (NAC 10 mM) and blotted at 24 h with no
further treatment (upper panel) or following 4 h of treatment with bafilomycin A1 (lower panel). Representative data from an experiment performed in triplicate
is shown. (F) The effects of NAC are seen in HeLa cells. Hela cells were treated under control conditions or with NAC (15 mM), trehalose, or trehalose and NAC
for 24 h before analysis by western blot. All experiments were carried out in the presence of a saturating dose of bafilomycin for the last 4 h. Note that HeLa cells
have very low levels of LC3-1. (G) Cystamine can inhibit basal autophagy. COS-7 cells were treated with 250 mM cystamine for 48 h, the last 4 h also being in
the presence of bafilomycin before being analysed by western blot. Error bars in all panels represent SEM from at least three independent experiments performed
in triplicate (∗P , 0.05, ∗∗P, 0.01, ∗∗∗P , 0.001).
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represent decreased synthesis, rather than increased autophago-
some/lysosome fusion (21). Interestingly, while co-treatment
with trehalose and cystamine resulted in no change in LC3-II
levels (data not shown), pre-treatment with cystamine did
impair induction of autophagy, consistent with the requirement
for cystamine to be metabolized to the glutathione precursor
L-cysteine in order to influence autophagy (Fig. 2B). Note that
while glutathione cannot directly penetrate cells, extracellular
glutathione is metabolized by g-glutamyl-transferase to ulti-
mately form cysteine, which is readily taken up.
Thiol antioxidants can impair basal autophagy
As thiol antioxidants seem to be able to profoundly impair
induced autophagy, we examined whether they could impair
autophagy induced by mTOR inhibition and basal autophagy.
We found that NAC impaired the increase in LC3-II associated
with rapamycin treatment and also decreased LC3-II compared
with the basal state (Fig. 2D). We confirmed the effect of NAC
on basal and inducible autophagy in human primary cortical
neurons, with and without bafilomycin (Fig. 2E) and in HeLa
cells (Fig. 2F). Pre-treatment with cystamine had similar effects
on basal autophagy (Fig. 2G). We next employed a second autop-
hagy assay to confirm our findings. We used a HeLa cell line con-
stitutively expressing LC3 tagged to both green fluorescent
protein (GFP) and red fluorescent protein (RFP). Due to the
different pKa of these two fluorophores when present on the
autophagosome, both red and green are seen, but when autopha-
gosomes fuse with the lysosome, the green signal is quenched in
the low pH environment, and only red is seen. Using this tech-
nique, it is therefore possible to differentiate and count red
dots (autophagolysosomes and autophagosomes), green dots
(autophagosomes) and red dots that are not also green (autopha-
golysosomes). This second autophagy measure was consistent
with NAC impairing both basal and inducible autophagy by inhi-
biting autophagosome synthesis rather than enhancing fusion
(Fig. 3A and B).
NAC inhibits the clearance of disease-related proteins
As high doses of NAC impair autophagy, we tested whether it
also impaired clearance of disease-related autophagy sub-
strates in neuronal cell models. We found that NAC was
able to impair the clearance of an autophagy substrate, hae-
magglutinin (HA)-tagged mutant A53T a-synuclein, a
soluble protein that causes a form of familial PD (22). NAC
also significantly impaired the ability of rapamycin to
enhance clearance of this substrate (Fig. 4A). Similarly, we
found that NAC increased the percentage of cells with aggre-
gates of enhanced green fluorescent protein (EGFP)-tagged
mutant huntingtin exon 1 and impaired the ability of trehalose
to decrease the percentage of cells with aggregates, a phenom-
enon that is autophagy dependent (8) (Fig. 4B and C).
Inhibition of autophagy by antioxidant drugs is not
restricted to thiol antioxidants
In order to test whether autophagy inhibition by antioxidants is
thiol specific, we tested the non-thiol antioxidant vitamin E
(DL-alpha tocopherol). Vitamin E has been proposed as a
treatment for neurodegenerative disease and has been used
in major trials in PD and HD (23,24). We found that
vitamin E was similarly able to impair trehalose-induced and
basal levels of LC3-II in COS-7 cells, mouse primary cortical
neurons and HeLa cells (Fig. 5A–D). Like NAC, it was able to
strongly inhibit the degradation of A53T a-synuclein and
prevent the enhanced degradation of this substrate in the pres-
ence of rapamycin (Fig. 5E).
As chemical antioxidants often have pleiotropic effects (and
therefore could have an influence on autophagic activity by
mechanisms other than decreasing oxidative stress), we inves-
tigated the effect on autophagy of genetic up-regulation of
defences against oxidative stress. Previously, over-expression
of the superoxide dismutase gene (SOD2), which scavenges
superoxide, has been shown to inhibit induced autophagy
associated with increased ROS (25). SOD2 is localized to
the mitochondrial matrix, while SOD1 is mainly cytosolic
with a smaller fraction in the mitochondrial intermembrane
space. In order to test whether SOD1 over-expression can
also inhibit autophagy, we transiently over-expressed SOD1
and observed the effect on levels on LC3-II in the presence
of bafilomycin. As expected, over-expression of SOD1
decreased basal LC3-II levels (Fig. 5F).
Antioxidants affect multiple canonical mechanisms
regulating autophagy
In order to examine potential mechanisms by which antioxi-
dants may influence autophagy, we examined their effect on
the mTOR pathway, a classical negative regulator of autop-
hagy, by looking for changes in the phosphorylation status
of an mTOR kinase substrate 4E binding protein 1 (4E-BP1)
and a protein dependent on mTOR substrate kinase activity,
ribosomal protein S6 (S6). Vitamin E enhanced the activity
of mTOR but, surprisingly, NAC appeared to be inhibiting
mTOR activity—an effect that would be expected to increase,
rather than decrease, autophagy (Fig. 6A and B). Thus, while
vitamin E influences the mTOR pathway in a way which is
consistent with autophagy inhibition, this was not the case
for NAC.
Starvation-induced autophagy is associated with increased
levels of ROS and has been shown to be mediated by the acti-
vation of c-Jun N-terminal protein kinase 1 (JNK1) which, in
turn, phosphorylates Bcl-2 and causes it to dissociate from
Beclin 1 (26). NAC is able to inhibit both ROS accumulation
and autophagy in starved cells (12). Given this, and the unex-
pected effect of NAC on mTOR, we next tested the effect of
thiol antioxidants on JNK activation. NAC and glutathione
inhibited the activation of JNK and decreased the phosphoryl-
ation of Bcl-2 (Fig. 6C and D). Previous work has shown that
oxidative stress in the form of hydrogen peroxide can increase
the expression of Beclin-1 and thus induce autophagy (27).
We did not find that thiol antioxidants or vitamin E had any
significant effect on levels of Beclin-1 (Fig. 6D and E).
Superoxide has recently been described as a specific ROS
regulating autophagy, though the exact mechanism remains
unknown (25). We found that the superoxide-generating
agent, menadione, strongly increased levels of LC3-II at
time points as short as 45 min (though, as superoxide is very
rapidly converted to hydrogen peroxide, the actual ROS
Human Molecular Genetics, 2010, Vol. 19, No. 17 3417
involved in this process is unclear) (Fig. 6F). Menadione had
the opposite effect of thiol antioxidants by enhancing JNK and
Bcl-2 phosphorylation, but had no effect on mTOR activity or
Beclin-1 expression (Fig. 6F). In summary, these results
suggest that vitamin E enhances the activity of mTOR, an
effect which would be consistent with autophagy inhibition.
Thiol ROS scavengers such as NAC inhibit mTOR (which
would be expected to induce autophagy) but decrease the
phosphorylation of JNK and Bcl-2 which will inhibit autop-
hagy, while the superoxide-generating agent menadione
increases levels of LC3-II and the phosphorylation of JNK
and Bcl-2.
Thiol antioxidants and over-expression of SOD exacerbate
the phenotype seen in Drosophila models of polyglutamine
disease
To investigate the potential pathophysiological significance of
our findings, we used a Drosophila model of HD that expresses
exon 1 of huntingtin with an expanded polyglutamine tract
Figure 3. NAC impairs autophagosome synthesis in a second assay. (A) NAC significantly decreases both autophagosome and autophagolysosome number.
HeLa cells expressing RFP and GFP tagged LC3-II as described in Materials and Methods were treated as shown (NAC 10 mM), before being fixed and subjected
to automated counting of red and green dots. Representative confocal microscopy images are shown. (B) Results of automated cell counting. The left panel shows
the number of green dots (autophagosomes) and the right panel the number of red minus green dots (autophagolysosomes) relative to control. The graphs shown
represent the mean results from five experiments performed in triplicate. Error bars represent SEM (∗P , 0.05, ∗∗∗P , 0.001, NS, non significant).
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Figure 4. NAC impairs clearance of autophagy substrates. (A) Expression of HA-tagged A53T a-synuclein [a mutant form of the protein that does not form
visible aggregates in these cells (22)] was induced for 48 h before transgene expression was switched off. During the switch-off period, cells were treated as
shown (NAC 10 mM, Rap, rapamycin) for 24 h before being harvested and analysed by western blotting. The graph shows densitometric analysis with
results for NAC set to 100%. (B) NAC increases aggregation of mutant huntingtin. Expression of EGFP tagged huntingtin exon 1 with an expanded (74Q) poly-
glutamine repeat was induced for 8 h (47). The transgene was then switched off and the cells treated as shown (NAC 10 mM) for 72 h before fixing and counting.
The graph shows percentage of cells with aggregates for each condition for a representative experiment, error bars represent standard deviation. For all other
panels, error bars represent SEM (∗P, 0.05, ∗∗∗P , 0.001, NS, non significant).
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Figure 5. Vitamin E and over-expression of SOD can also inhibit autophagy. (A) Vitamin E can inhibit trehalose-induced autophagy. COS-7 cells were treated
with trehalose and increasing doses of vitamin E (DL-alpha tocopherol, VitE) for 24 h, before treatment for 4 h with bafilomycin, in a similar manner to the
experiments presented in Figure 2A–C. The densitometric analysis shows error bars and statistics from three experiments performed in triplicate as in
Figure 2A–C. (B) Vitamin E can inhibit basal autophagy. COS-7 cells were treated with 250 mM vitamin E before being analysed by western blot in a
similar manner to Figure 2G. (C) The effects of vitamin E on autophagy are also seen in primary neuronal culture. Differentiated mouse primary cortical neur-
ones were treated as indicated with bafilomycin added for the last 4 h. (D) Vitamin E has similar effects on basal and induced autophagy in HeLa cells. HeLa
cells were treated under control conditions or with vitamin E (250 mM), trehalose or trehalose and vitamin E for 24 h before analysis by western blot. All exper-
iments were carried out in the presence of a saturating dose of bafilomycin for the last 4 h. (E) Vitamin E can inhibit the clearance of autophagy substrates
associated with neurodegenerative disease. Expression of HA-tagged A53T a-synuclein was induced for 48 h before the cells were treated as shown
(vitamin E, 250 mM) for 24 h before being harvested and analysed by western blotting. The graph shows densitometric analysis with results for control set to
100%. (F) COS-7 cells were transfected with human SOD1 and allowed to express for 48 h, the last 4 h with bafilomycin. A representative western blot is
shown. The graph shows densitometric analysis from five independent experiments performed in triplicate with pcDNA (control) set to 100%. Error bars rep-
resent SEM (∗P, 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001, NS, non-significant) for all panels.
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Figure 6. Antioxidants affect different canonical mechanisms regulating autophagy. (A) Vitamin E increases phosphorylation of mTOR substrates. COS-7 cells
were treated with 250 mM vitamin E, rapamycin or rapamycin and vitamin E for 24 h before harvest. Lysates were run simultaneously on two gels and probed for
mTOR substrates and loading controls. 4E-BP-1 (an mTOR substrate) has multiple phosphorylation sites and runs as four bands with the upper bands represent-
ing predominantly phosphorylated forms. Vitamin E increases phosphorylation compared with control and impairs the ability of rapamycin to inhibit the phos-
phorylation of 4E-BP1. These results were confirmed using a second substrate, ribosomal protein S6. T4E-BP denotes total 4E-BP, P4E-BP phosphorylated
4EBP, TS6 total S6 and PS6 phosphorylated S6. Dk exp denotes dark exposure and Lt exp light exposure. (B) NAC decreases phosphorylation of mTOR sub-
strates. This experiment was performed in a similar manner to (A) but using 25 mM NAC instead of vitamin E. Representative western blots are shown. (C) Thiol
antioxidants decrease JNK phosphorylation. COS-7 cells were treated for 24 h with 25 mM NAC or glutathione and the phosphorylation of JNK measured using a
FACE ELISA kit. The graph shows phosphorylated (PJNK)/total JNK (TJNK) with control set to 100%. (D) Thiol antioxidants decrease Bcl-2 phosphorylation.
COS-7 cells were treated as shown for 24 h and blotted for phosphorylated Bcl-2 (PBcl-2) before stripping and reprobing for total Bcl-2 (TBcl-2). The graph
represents densitometric analysis. (E) Vitamin E has no effect on Bcl-2 phosphorylation. COS-7 cells were treated for 24 h with vitamin E or DMSO control and
analysed by western blot for levels of phosphorylated Bcl-2 and Beclin 1. No significant differences were seen. (F) The superoxide generating agent menadione
increases LC3-II and phosphorylation of JNK and Bcl-2, but has no effect on mTOR substrates or Beclin-1 expression. COS-7 cells were treated with 100 mM
menadione for 1 h prior to harvest and analysed by western blot for LC3-II, phosphorylated Bcl-2 and total Bcl-2. The graphs show densitometric analysis with
control set to 100%. The effect of menadione and vitamin E on JNK phosphorylation was analysed in a similar way to (C). All panels represent results from three
independent triplicate experiments, error bars represent SEM (∗P, 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001, NS, non-significant).
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(Q120) in the eye (28). Each eye is made up of many ommatidia
which are, in turn, made of eight rhabdomeres, seven of which
are visible. The severity of the disease phenotype was measured
by counting the number of rhabdomeres per ommatidia—the
more severe the degeneration, the fewer rhabdomeres are
seen. We treated these flies with increasing doses of NAC and
found that low doses of NAC had no significant effect, while
high doses exacerbated the neurodegenerative phenotype
(Fig. 7A). We used a dose of NAC that did not, on its own,
exacerbate the phenotype in the HD flies and tested it alone
and in combination with the autophagy-enhancing agent rapa-
mycin. We found that both NAC and cystamine significantly
impaired the ability of rapamycin to rescue the HD phenotype
(Fig. 7B). Note that rapamycin has been shown to suppress poly-
glutamine toxicity in flies in an autophagy-dependent manner
(29). Though it is possible that rapamycin is inhibiting the
rescue seen with cystamine, rather than the other way around,
the idea that cystamine is inhibiting autophagy induction is con-
sistent with our cell biology findings. Furthermore, the fact that
NAC was able to ameliorate the rescue seen with rapamycin,
while exhibiting no significant rescue by itself, suggests that
thiol antioxidants are able to inhibit the therapeutic effect of
rapamycin.
In order to more specifically examine the role of oxidative
stress, we used a second fly model of neurodegeneration
which expresses a naked expanded (Q48) polyglutamine
stretch which results in a clearly visible eye phenotype. We
crossed these flies with flies over-expressing cytosolic and
mitochondrial isoforms of SOD, using w118 isogenic males
as controls (30–33). We found that over-expression of either
SOD1 or SOD2 had no obvious effect on the eye in control
flies, but dramatically enhanced the neurodegenerative pheno-
type seen in Q48 flies (Fig. 7C).
NAC and vitamin E can inhibit autophagic flux in
zebrafish and increase aggregation of mutant huntingtin in
zebrafish models of polyglutamine disease
Studies in larval zebrafish have previously demonstrated that
LC3-I to LC3-II conversion occurs from 32 h post-fertilization
onwards and that changes in LC3-II levels could be measured
in the presence of lysosomal protease inhibitors (34). In agree-
ment with this, we observed a concentration-dependant
increase in LC3-II levels in larval zebrafish treated with
ammonium chloride, with 100 mM ammonium chloride pro-
viding reliable and dramatic increases in levels of LC3-II
(Fig. 8A). Ammonium chloride blocks autophagosome/
lysosome fusion (35) and this assay therefore allows us to
investigate in vivo changes in autophagic flux (as opposed to
changes in steady-state levels of LC3-II) in much the same
way as treatment with bafilomycin in cell cultures.
We found that co-treatment with NAC or vitamin E and
ammonium chloride caused significant decreases in LC3-II
levels compared with ammonium chloride alone, suggesting
that these compounds are able to inhibit autophagic flux
(Fig. 8B and C). We tested the pathological relevance of
Figure 7. Thiol antioxidants and over-expression of SOD can enhance the phonotype in Drosophila models of polyglutamine disease. (A) High-dose NAC
exacerbates mutant huntingtin phenotypes. Flies expressing mutant Q120 huntingtin exon-1 in the eye show an increase in neurodegeneration when treated
with high dosage of NAC (5–10 mg/ml), while no such phenomena is seen in Q23 control flies. (B) The rescue in Q120 flies seen with rapamycin is abolished
when rapamycin is combined with NAC or cystamine. Flies expressing mutant huntingtin exon-1 in eyes showed a significant decrease in neurodegeneration
when treated with 100 mM cystamine or 2 mM rapamycin. Neurodegeneration was reversed to control level when the Q120 flies were treated with 500 mg/ml
NAC or 100 mM cystamine combined with 2 mM rapamycin (∗P , 0.05, ∗∗P , 0.01, NS, non-significant). (C) Over-expression of SOD can exacerbate neuro-
degeneration. Male flies expressing a naked polyglutamine tract (Q48) in the eye show a dramatic increase in neurodegeneration when crossed with flies over-
expressing SOD1 or SOD2, while over-expression of SOD1 (Sod.A) or SOD2 has no such effect in control flies.
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Figure 8. NAC and vitamin E can inhibit autophagic flux and increase aggregation in a zebrafish model of Huntington’s disease. (A) Ammonium chloride causes
significant increases in levels of LC3-II in zebrafish larvae, consistent with an ability to block autophagosome/lysosome fusion. (B and C) In zebrafish,
co-treatment with either NAC or vitamin E significantly decreases the levels of LC3-II seen in the presence of ammonium chloride, consistent with their
ability to decrease autophagic flux. The panels show western blots for LC3-II against tubulin loading controls. The graphs represent densitometric analysis
of three independent experiments. (D and E) NAC and vitamin E increase aggregation, while the autophagy-inducing drugs rapamycin and clonidine decrease
aggregation, of EGFP mutant huntingtin in the retina of transgenic zebrafish. (D) shows the average number of aggregates per retina in each condition relative to
control. Representative images taken from the retina are shown in (E) with huntingtin aggregates indicated by arrows. (A, control condition; B, NAC treatment;
C, vitamin E; D, rapamycin treatment; E, rapamycin and NAC; F, clonidine treatment; G, clonidine and NAC). Note that the rescue seen with rapamycin or
clonidine is abolished by co-treatment with NAC (∗P , 0.05, ∗∗P , 0.01, ∗∗∗P , 0.001, NS, non-significant).
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this effect by treating transgenic EGFP-HDQ71 zebrafish and
counting huntingtin aggregates in the retina. We found that
NAC and vitamin E significantly increased the number of
aggregates of mutant huntingtin compared with control
(Fig. 8D and E). As predicted, treatment with the
autophagy-inducing agents rapamycin and clonidine signifi-
cantly decreased huntingtin aggregation, but this effect was
lost when treatment with these compounds was combined
with NAC (Fig. 8D and E). To our knowledge, this is the
first demonstration of changes in both autophagic flux and
aggregation of autophagy substrates in a vertebrate model of
polyglutamine disease.
NAC inhibits starvation-induced autophagy in mice
In order to investigate the physiological relevance of our find-
ings, we examined the effect of NAC on starvation-induced
autophagy in mice. As expected, starvation strongly increased
hepatic LC3-II levels, but this increase was significantly
smaller in mice that had been pre-treated with NAC (Fig. 9).
We chose the liver as a readout as it is the best-characterized
organ for changes in autophagic activity and also has a signifi-
cant physiological role in adaptation to starvation (36). While
no significant changes in LC3-II levels were seen in brain
(data not shown), this result was expected as the brain is an
organ that is protected from decreases in nutrient availability
and therefore would not be expected to show a strong
up-regulation of autophagy in response to relatively short
periods of starvation. Furthermore, since these experiments
could not be performed in the presence of a blocker of autop-
hagosomal/lysosomal fusion, the changes in autophagic flux at
the level of synthesis are much more difficult to detect outside
of organs which show a strong physiological response to brief
periods of starvation.
DISCUSSION
The study presented here contains a number of novel findings.
First, we show that drugs that up-regulate autophagy and have
been proposed for use in human neurodegenerative disease do
not cause detectable increases in ROS production. However,
the up-regulation of autophagy by these drugs, and, indeed
basal autophagy, are still inhibited by antioxidant drugs,
suggesting that some level of ROS production or redox signal-
ling is required for the normal regulation of autophagy. We
show that antioxidants have effects on different classic autop-
hagy regulatory pathways, consistent with their ability to
inhibit autophagy. Vitamin E has an effect on the mTOR
pathway, while thiol-containing antioxidants, such as NAC,
decrease the phosphorylation of JNK and Bcl-2. Given the
central role of superoxide in autophagy and our observation
that menadione has opposite effects on the phosphorylation
of JNK and Bcl-2 to NAC, it is possible that NAC exerts its
effects by acting downstream of superoxide. However, as the
rate constant of thiol groups for the reaction with superoxide
is significantly less than that of the abundant SOD, it seems
unlikely that superoxide is being directly scavenged. Alterna-
tively, the increased cell thiol content may be blocking or
reversing redox changes that occur downstream of superoxide
production. We also show in vivo pathological and physiologi-
cal relevance for these findings including, what is to our
knowledge, the first ever vertebrate model of polyglutamine
disease which allows quantification of changes in autophagic
flux in conjunction with levels of pathological autophagic sub-
strates.
We believe that the data presented here may have signifi-
cant application to the design of treatment for human neurode-
generative disease. The idea that oxidative stress is
pathological in the context of these diseases, and that decreas-
ing oxidative stress is therefore a likely therapeutic strategy,
has become a paradigm in the field. Our data suggest that
low levels of some forms of ROS or redox signals are essential
for autophagy. At least in diseases caused by aggregate-prone
proteins which are autophagy substrates, the potential benefits
of ROS scavenging may therefore be counterbalanced by an
increased load of toxic protein. This is of significance, as sup-
plements with putative antioxidant properties are commonly
taken in the general population and even more frequently in
those with neurodegenerative disease. In a previously pub-
lished study from our group, we found that over two-thirds
of HD patients were routinely taking supplements with puta-
tive antioxidant activity, a similar figure to other published
series of PD patients (37,38). Furthermore, previously pub-
lished series also suggest that many of these patients are
unaware of any possible side effects of these supplements
Figure 9. NAC inhibits the increase in hepatic LC3-II in starved mice. Mice underwent two periods of starvation of 24 h separated by 90 min of access to food.
Following sacrifice, the liver was analysed by western blotting for levels of LC3-II. The graph represents the mean results from five mice per group with star-
vation (positive control, Starv) set to 100%. Error bars represent SEM (∗∗P, 0.01, ∗∗∗P , 0.001, NS, non significant).
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and do not tell their treating physician they are taking them
(38). This could be a potentially significant confounder in
any trial of autophagy-enhancing drugs and indeed it is concei-
vable that long-term inhibition of autophagy with these agents
may even exacerbate the disease course. The only clinical trial
of vitamin E in HD published to date showed non-significant
worsening of all primary outcome measures, while trials of
vitamin E in PD have similarly failed to show striking
benefit or harm (23,24).
We do not suggest that treatments aimed at ameliorating
oxidative stress may not have their place as therapy, but
rather that better understanding of their interaction with
other cellular processes may allow for more appropriately
designed (and therefore more effective) treatment. For
example, since the effects of antioxidants on autophagy
appear dose-dependent, it is possible that dose may be
crucial in balancing the effects of these drugs, and that
higher doses may not necessarily mean greater efficacy. This
may be of particular relevance as higher doses of some antiox-
idants have been proposed for use in HD (3). Additionally, the
mechanisms of autophagy regulation by NAC and vitamin E
appear distinct (as one might expect from such different anti-
oxidant compounds), indicating that the interaction with
autophagy may vary depending on the nature of the antioxi-
dant used. Similarly, it is possible that antioxidant treatment
at a time point in the disease when autophagic defence
responses have become overwhelmed, or targeting specific
cellular compartments, may be more efficacious. Understand-
ing the interaction between various agents that may modify the
progression of neurodegenerative diseases has significant
current relevance, as clinical trials of both autophagy-
enhancing drugs (39) and antioxidant therapies (40) have
been performed and combination treatments may appear an
attractive therapeutic strategy. Our data suggest that some
combinations that appear attractive on the basis of current
knowledge (such as rapamycin and cystamine) may not be
beneficial.
The demonstration that NAC inhibits the up-regulation of
autophagy in vivo may have clinical utility outside of neurode-
generation. NAC has a long safety record in the treatment of
acetaminophen poisoning in humans where it is used intrave-
nously at high doses, resulting in serum concentrations com-
parable to those used in cell and mouse models described
here (41). Some malignant tumours up-regulate autophagy as
a way of surviving chemotherapy/radiotherapy and to
provide nutrient recycling in the avascular tumour core.
Autophagy inhibitors may be potential cancer therapies in
this context (42). NAC may be particularly attractive in this
regard as our data suggest it has the unusual combination of
properties of inhibiting both mTOR (which may inhibit
tumour growth) and autophagy. Thus, while long-term inhi-
bition of autophagy is likely to be deleterious, it may well
be possible to use potent, reversible autophagy inhibitors
safely for short periods. For these applications, NAC may be
an attractive candidate therapy.
The apparently intimate relationship between ROS and
autophagy is just one example of how our appreciation of
ROS has moved beyond regarding them simply as a dangerous
and unwanted by-product of metabolism. Enhanced under-
standing of the interaction between these cellular processes
is likely to have application to the treatment of human
diseases.
MATERIALS AND METHODS
All reagents were from Sigma-Aldrich unless otherwise specified.
Cell culture
COS-7 (African green monkey kidney cells) and HeLa (from
human cervical carcinoma origin) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum, 100 U/ml streptomycin/penicillin and
2 mM L-glutamine. They were maintained at 378C and 5%
CO2. Cells were seeded in six well plates (with cover slips
for counting experiments) at densities to allow 60–80% conflu-
ence by the time lysates were collected for western blotting.
Counting experiments were seeded at higher density to allow
80% confluence prior to transfection. Stable inducible A53T
alpha synuclein and HD exon 1 Q74 PC12 cells were cultured
in DMEM supplemented with 10% horse serum, 5% fetal
bovine serum, 2 mM L-glutamine, 100 U/ml penicillin/strepto-
mycin, 50 mg/ml G418 and 70 mg/ml Hygromycin B. They
were kept at 378C and 10% CO2 and expression was induced
by treating them with 1 mg/ml of doxycycline for 48 h (alpha
synuclein) or 8 h (HD exon 1), before washing to remove dox-
ycycline and therefore turn off inducible transgene expression.
ReNcell CX cells, an immortalized human neuronal progenitor
cell line with the ability to readily differentiate into cortical
neurons, were cultured according to the manufacturer’s instruc-
tions (Chemicon, Millpore, MA, USA). Cells were grown in
ReNcell NSC maintenance medium supplemented with 20 ng/
ml bFGF and 20 ng/ml EGF. Cells were seeded on laminin
coated plates and differentiation was initiated with media con-
taining no growth factors for 1 week prior to starting the exper-
iment. Mouse primary cortical neuronal cultures were prepared
as described previously (43). Briefly, cortices were dissected
from 15- to 16-day-old C57BL/6 mouse embryos and mechani-
cally dissociated in PBS (Ca2+- and Mg2+-free) supplemented
with glucose (33 mM). Neurons were plated into multi-well
plates coated with 20 mg/ml poly-D-lysine and were maintained
in DMEM, supplemented with B-27 (Gibco), 2 mM glutamine,
100 mg/ml streptomycin and 60 mg/ml penicillin, at 378C and
5% CO2. Cultures were used after 6–7 days in vitro (DIV)
when the majority of cells were neuronal and there were no
detectable glial elements.
Reagents
Autophagy modifiers were used at the following concen-
trations. Rapamycin (LC Laboratories) 200 nM, bafilomycin
A1 400 nM, trehalose, 100 mM, Menadione 100 mM. Rapamy-
cin was dissolved in DMSO and controls for rapamycin
were treated with an equivalent volume of DMSO. Menadione
was dissolved in ethanol and menadione controls treated with
an equivalent volume of ethanol.
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Measurement of ROS
HeLa cells were seeded in a 24-well plate and left overnight.
They were incubated with 30 mM DCFDA or Carboxy-H2-
DCFDA for 10 min, 5 mM MitoSOXTM red for 10 min or
15 mM dihydrorhodamine 123 (all Molecular probes, Invitrogen)
for 30 min, before being washed twice and left in rich media, or
media containing the relevant treatment. One millimolar hydro-
gen peroxide (H2O2) (Fisher Scientific) and 100 mM menadione
and starvation in HBSS were used as positive controls. Fluor-
escence was then measured using a CytoFluor Series 4000
multi well plate reader (PerSeptive Biosystems). The plates
were returned to an incubator between readings. DCFDA and
dihydrorhodamine were measured at excitation 485, emission
530 and MitoSOXTM red at 530/620.
JNK phosphorylation assay
JNK phosphorylation was measured using a colorimetric
fast-activated cell-based enzyme-linked immunosorbant
assay (FACE ELISA) kit (Active Motif). COS-7 cells were
seeded in a 96-well plate and left overnight before being
treated for 24 h. They were then fixed, blocked and probed
with antibody to phosphorylated or total JNK as per manufac-
turer’s instructions. Absorbance was measured using an
OPTImax microplate reader at 450 nm.
Western blot analysis
Prior to analysis, cells were washed with PBS. They were then
lysed in radioimmunoprecipitation assay buffer [150 mM
NaCl, 1% NP40, 0.5% NaDoC, 0.1% SDS, 50 mM Tris, pro-
tease inhibitors (Roche diagnostics)]. A Bio-rad protein
assay was then carried out to allow equal loading. The
lysates were subjected to a sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS–PAGE) (12%) and proteins
were transferred to PVDF. Blots were probed with horseradish
peroxidase-conjugated anti-mouse or anti-rabbit IgG at
1:2000. Bands were visualized using ECLTM detection
reagent (Amersham). Densitometry was carried out using
Image J software and statistically analysed using factorial
analysis of variance (ANOVA) using STATVIEW v4.53
(Abacus Concepts) where the control value is set to 100%.
The densitometry represents the means of at least three exper-
iments performed in duplicate or triplicate.
Quantification of aggregation
Aggregates were visualized and counted by fluorescence
microscopy as previously described (17). Cells were washed
once with PBS before being fixed for 20 min in 4% parafor-
maldehyde in PBS. The cells were washed again in PBS
before being mounted in an antifade reagent containing
3 mg/ml 4′,6-diamidino-2-phenylindole (DAPI) to facilitate
nuclear staining. Five hundred EGFP positive cells per cover
slip were counted by an observer blind to the identity of the
slides. The results of the counting experiment were analysed
by unconditional logistic regression using SPSS 6.1 (SPSS,
Chicago, IL, USA). Images were obtained using a Nikon
Eclipse E600 microscope attached to a Nikon DXM1200
digital camera using Nikon ACT-1 acquisition software
(Nikon Inc.).
Automated cell counting
HeLa cells expressing RFP/GFP tagged LC3 were seeded on
cover slips and treated overnight in the appropriate media.
They were then washed in PBS, fixed with 4% paraformalde-
hyde and mounted in Prolong Gold antifade reagent with
DAPI (Invitrogen). The number of red dots and green dots
per cell was counted using a Cellomics ArrayScan VTI high
content screening reader using the Spot detector V3 Cellomics
bioapplication. One thousand cells were counted per cover slip
and each experiment was done in triplicate at least four times.
Drosophila experiments
Pseudopupil analysis was performed as previously described
(44) crossing virgins of the genotype y w; P,2.4 (Q120) with
w1118 isogenic males. The progeny of the above cross was
reared on instant fly food containing 500 mg/ml NAC,
100 mM cystamine or 2 mM rapamycin. Combination treat-
ments were done by adding 500 mg/ml NAC or 100 mM cysta-
mine to 2 mM rapamycin. Control flies grown in absence of
drug were fed with instant fly food with 0.02% DMSO. Flies
were treated with drugs during both the larval and adult
stage. To assess the effect of different treatments on Q120
flies, t-test analysis was performed on four independent exper-
iments, each involving the counting of 15 ommatidia was
scored from each of 10 individuals, 3 days post-eclosion.
Q23 control flies (Q23, P{GMR-HD.Q23) were used to
compare the effect of increasing doses of NAC on eye
phenotype. To study the effect of SOD on flies expressing
an expanded polyglutamine stretch (P{UAS-Q48.
myc/flag}31(30), virgins of the genotype w; GMR-GAL4;
UAS.Q48myc/flag (Q48) were crossed with males transgenic
for SOD, either P{UAS-Sod2.M}UM83(31), or P{UAS-Sod.A}
B36(32) or with w1118 isogenic males as control. Overexpression
of SOD in the eye does not affect eye phenotype. Male
flies expressing either SOD1 (UAS-Sod.A, w; GMR-Gal4/
UAS-Sod.A) or SOD2 (UAS-Sod2, w; GMR-Gal4/UAS-Sod2.M)
were comparable to control flies (GMR-Gal4, P{GAL4-ninaE.
GMR}12) to investigate the effect of SOD over-expression with
no polyQ construct. Fly crosses and experiments were performed
at 258C. All crosses for individual experiments were performed at
the same time and under the same conditions.
Zebrafish experiments
Maintenance of stocks and collection of embryos. All zebrafish
husbandry and experiments were performed in accordance
with UK legislation under a license granted by the Home
Office and with local ethical approval. Zebrafish were reared
under standard conditions on a 14 h light:10 h dark cycle.
Embryos were collected from natural spawnings, staged
according to established criteria (45) and reared in embryo
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM Mg2SO4). Experiments measuring endogenous
LC3-II levels were performed on wild-type zebrafish of the
AB strain. Aggregate counting was performed using the
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heterozygous larvae from the transgenic rhodopsin::EGFP-
HDQ71 zebrafish line (46) (hereafter referred to as transgenic
HD zebrafish). Compound exposure experiments were per-
formed in the dark at 28.58C.
Determination of the maximum tolerated concentration of
compounds in larval zebrafish. Compound exposure exper-
iments were performed on wild-type larvae from 2 days post-
fertilization (d.p.f.) for 24 h. Concentration response assays
were performed over half-log intervals, from 10 mM to 1 mM
for ammonium chloride, 1 mM to 1 mM for clonidine, 1 mM
to 10 mM for NAC, 1–100 mM for rapamycin, 1 mM to
10 mM for DL-alpha tocopherol, to determine the maximum
non-toxic concentration for subsequent autophagy assays
(n ¼ 10 larvae per concentration).
Measuring endogenous LC3-II in larval zebrafish. LC3-II
assays were performed at the following concentrations:
ammonium chloride at 100 mM, NAC at 300 mM and 1 mM,
DL-alpha tocopherol at 100 mM and 1 mM for 24 h. Wild-type
larvae (n ¼ 30 per treatment group) at 2 d.p.f. were exposed to
NAC, DL-alpha tocopherol or embryo medium (untreated
control) for 20 h prior to compound replenishment and the
addition of ammonium chloride. Larvae were incubated in
compounds for a further 4 h then transferred to chilled tubes,
homogenized in lysis buffer then processed for western blot-
ting as described above.
Aggregate analysis in the transgenic HD zebrafish. Embryos
from out-crossed transgenic HD zebrafish were raised in
0.2 mM 1-phenyl-2-thiourea (PTU) from 1 to 3 d.p.f. to
inhibit pigment formation, screened for transgene expression
using EGFP fluorescence then washed twice in embryo
medium to remove PTU. From 3 to 7 d.p.f., transgenic HD
zebrafish larvae were dark-reared in embryo medium alone
or embryo medium containing either 300 mM NAC, 1 mM
DL-alpha tocopherol, 30 mM rapamycin, 30 mM clonidine
(compounds administered alone or in combination). Embryo
medium and compounds were replenished daily. At 7 d.p.f.,
larvae were anesthetized by immersion in 0.2 mg/ml
3-amino benzoic acid ethylester (MS222) then fixed using
4% PFA in PBS at 48C. Larvae were washed briefly in PBS,
allowed to equilibrate in 30% sucrose in PBS then embedded
in OCT medium (Tissue-Tek) and frozen on dry ice for sub-
sequent cryosectioning. Sections were cut at 10 mm thickness
using a Leica CM3050 cryostat and mounted in 80% glycerol
in PBS. The total number of GFP-positive aggregates was
counted over 100 mm of the central retina, either side of the
optic nerve using a Zeiss Axiophot2 microscope and mean
values were calculated using four fish (eight eyes) for
each treatment group. Data were compared using ANOVA
Representative images were taken using a Sony CCD digital
camera.
Mouse experiments. The mice experiments all complied with
Home Office project and personal animal licenses. Twenty
male C57BL/6 mice were used aged 35–42 days at the start
of the study. The mice were divided into four groups, each
containing five mice. After 3 weeks of acclimatization, two
groups received no treatment while the other two groups
were treated with NAC at 1% in their drinking water for
2 weeks. Following this, one of the control groups of mice
and one of the groups treated with NAC were starved by for
22.5 h before allowing them 90 min unrestricted access to
food. The following day, the same two groups were
again starved for 22.5 h before being sacrificed. The liver
was dissected and homogenized in lysis buffer [0.25 M Tris,
2.5% Triton, 150 mM NaCl and protease inhibitor cocktail
(Roche Scientific)] before being analysed by western blot.
Statistical analyses
P-values for densitometric analysis using multiple conditions
were performed using a factorial ANOVA using STATVIEW
v4.53 (Abacus Concepts). For densitometry involving two
conditions, a two-tailed paired student’s t-test was performed
on the untransformed data. P-values for counting aggregates
were calculated using odds ratio using SPSS Version 6.1 soft-
ware (SPSS). Experiments were performed at least three times
in triplicate unless otherwise indicated.
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